GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Buyback Yield %

LVTX (LAVA Therapeutics NV) Buyback Yield % : 0.00 (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

LAVA Therapeutics NV's current buyback yield was 0.00%.


LAVA Therapeutics NV Buyback Yield % Historical Data

The historical data trend for LAVA Therapeutics NV's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Buyback Yield % Chart

LAVA Therapeutics NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
- - -66.44 - -

LAVA Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of LAVA Therapeutics NV's Buyback Yield %

For the Biotechnology subindustry, LAVA Therapeutics NV's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LAVA Therapeutics NV's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's Buyback Yield % falls into.



LAVA Therapeutics NV Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

LAVA Therapeutics NV's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 41.536778
=0.00%

LAVA Therapeutics NV's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 43.653518
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.


LAVA Therapeutics NV Buyback Yield % Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


LAVA Therapeutics NV Business Description

Traded in Other Exchanges
Address
Yalelaan 62, Utrecht, UT, NLD, 3584 CM
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.